Cancer Research UK
Clinical Trials Unit Glasgow
 
 
 

Trials (Active)

The following trials are currently in set-up, open to recruitment or in follow-up. Please click on the trial Acronym to obtain details about the trial and to download the Initiation Slides.

Tumour
Site
Trial Acronym Trial Description
Brain PARADIGM
(BR32)
Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study.

PARADIGM-2
(BR36)
OlaPArib and RADIotherapy or olaparib and radiotherapy plus temozolomide in newly-diagnosed Glioblastoma stratified by MGMT status: 2 parallel phase I studies

Breast SOLD
(B138)
The "Synergism or Long Duration Study" - SOLD

GI SCOT
(GI145)
A Study of Adjuvant Chemotherapy in Colorectal Cancer.

RTL Advanced Study
(GI159)
An analysis of Relative Telomere Length (RTL) during chemotherapy in patients with advanced gastro-oesophageal adenocarcinoma.

RTL Peri-op Study
(GI160)
An analysis of Relative Telomere Length (RTL) during peri-operative chemotherapy in patients with operable gastric or gastro-oesophageal junction adenocarcinoma.

BALLAD
(GI210)
A TRIAL TO EVALUATE THE POTENTIAL BENEFIT OF ADJUVANT CHEMOTHERAPY FOR SMALL BOWEL ADENOCARCINOMA (IRCI-002).

PIONEER
(GI214)
A Phase I Study of Olaparib in Combination with Chemo-radiation in Locally Advanced Pancreatic Cancer.

PRECISION-PANC
(GI250)
Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

PRIMUS 001
An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation

PRIMUS 002
An umbrella phase II study examining two neo-adjuvant regimens (FOLFOX-A and AG) in resectable and borderline resectable Pancreatic Ductal AdenoCarcinoma (PDAC), focusing on biomarker and liquid biopsy development

Gyn DNA Methylation
(G75)
DNA Methylation as a Predictor for Response and Progression-Free Survival in Patients with Ovarian Cancer.

DNA Methylation
(G107)
A non-randomised, single centre, sample collection trial of changes in ovarian tumour DNA methylation following chemotherapy and at relapse.

PARAGON
(G129)
Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms.

BriTROC-1
(G134)
Sample collection study to investigate the role of Homologous Recombination Deficiency in platinum sensitivity in recurrent high grade serous ovarian cancer.

NiCCC
(G143)
A randomised phase II study of Nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent Clear Cell Carcinoma of the ovary or endometrium.

LMS study
(G144)
A Phase III Randomised Trial of Gemcitabine plus Docetaxel followed by Doxorubicin versus Observation for Uterus Limited, High Grade Uterine Leiomyosarcoma.

OPSROC
(G147)
A prospective randomized Phase III Trial of Carboplatin / gemcitabine / bevacizumab vs pegylated liposomal doxorubicin / gemcitabine / bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

LOGS
(G148)
A randomised phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer of peritoneal cancer (GOG-0281).

OCTOPUS
(G149)
A Randomised, Phase II Umbrella Trial of Weekly Paclitaxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer

HGUS
(G153)
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment (EORTC 62113-55115). EudraCT Number: 2013-000762-11.

CENTURION
An open-label, randomised, phase II trial of ruCaparib combined with Nivolumab +/- Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and fallopian tube cancer

Lung DIAPHRAGM
(L148)
Diagnostic and Prognostic biomarkers in the Rational Assessment of Mesothelioma.

ADSCaN
(L163)
A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer.

SYSTEMS-2
(L160)
A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma.

Misc. CUP ONE
(MI67)
A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary (CUP): incorporating the prospective validation of molecular classifiers in diagnosis and classification and exploratory metabonomics.

CAVA
(MI102)
A randomised controlled trial with associated qualitative research of venous access devices for the delivery of long-term chemotherapy.

Single-Agent HIPROC
(SA164)
A Phase I/Ib Trial of the Oral Hedgehog inhibitor, LY2940680, in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant, Recurrent Ovarian Cancer or Recurrent, Advanced, Solid Tumours.

FAK-PD1
(SA172)
A Phase I/IIA Study To Assess Safety. Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients with Advanced Solid Malignancies

Urology SAPROCAN
(U174)
Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer: a Phase I/randomised phase II study by the UK NCRI Prostate Clinical Studies Group

MADCAP
(U208)
A phase I/randomised phase II trial of abiraterone acetate or enzalutamide with or without idasanutlin (RO5503781) in patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) who have not previously received docetaxel.

ATLANTIS
(U225)
An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer.

SPECTRE
(U233)
Combined Suppression Of Cholesterol Bioavailability And Androgen Deprivation Therapy To Treat Castration Resistant Prostate Cancer.